Prudden HJ, Tatoud R, Janes H, Wallace S, Miller V, Bekker LG, Donnell D. Perspectives on Design Approaches for HIV Prevention Efficacy Trials. AIDS Res Hum Retroviruses (2023) Sep 4. doi: 10.1089/AID.2022.0150. Epub ahead of print. PMID: 37392020.

Tatoud, R., Prudden, H, Slack, C., Shattock, R., Anklesaria, P., Bekker, L.-G., Buchbinder, S. Experimental Medicine for HIV Vaccine Research and Development. Vaccines (2023), 11, 970.

Why people living with HIV must be included in non-HIV clinical trials (2022). Position Paper. EATG.

Henderson M, Fidler S, Mothe B, Grinsztejn B, Haire B, Collins S, Lau JSY, Luba M, Sanne I, Tatoud R, Deeks S and Lewin SR. (2022), Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19. J Int AIDS Soc., 25: e25882.

Tatoud R, Snow W and Esparza J (2021), A transformed global enterprise for an HIV vaccine. J Int AIDS Soc., 24: e25822.


Bekker LG, Tatoud R, Dabis F, Feinberg M, Kaleebu P, Marovich M, Ndung’u T, Russell N, Johnson J, Luba M, Fauci AS, Morris L, Pantaleo G, Buchbinder S, Gray G, Vekemans J, Kim JH, Levy Y, Corey L, Shattock R, Makanga M, Williamson C, Dieffenbach C, Goodenow MM, Shao Y, Staprans S, Warren M, Johnston MI. The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet. 2020 Feb 1;395(10221):384-388. doi: 10.1016/S0140-6736(19)32682-0. Epub 2019 Dec 2. PMID: 31806257.

Paximadis M, Perez Patrigeon S, Rajasuriar R, Tatoud R, Scully E, Arbuthnot P. Hepatitis B and HIV-1 2019 IAS Cure Forum: lessons and benefits from interdisciplinary research. J Virus Erad. 2019 Nov 4;5(4):234-244. PMID: 31754448; PMCID: PMC6844409.

Nadai Y, Held K, Joseph S, Ahmed MIM, Hoffmann VS, Peterhoff D, Missanga M, Bauer A, Joachim A, Reimer U, Zerweck J, McCormack S, Cope AV, Tatoud R, Shattock RJ, Robb ML, Sandstroem EG, Hoelscher M, Maboko L, Bakari M, Kroidl A, Wagner R, Weber J, Pollakis G, Geldmacher C. Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence. Front Immunol. 2019 Apr 24;10:717. doi: 10.3389/fimmu.2019.00717. PMID: 31105688; PMCID: PMC6492543.

Joseph S, Quinn K, Greenwood A, Cope AV, McKay PF, Hayes PJ, Kopycinski JT, Gilmour J, Miller AN, Geldmacher C, Nadai Y, Ahmed MI, Montefiori DC, Dally L, Bouliotis G, Lewis DJ, Tatoud R, Wagner R, Esteban M, Shattock RJ, McCormack S, Weber J. A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes. Front Immunol. 2017 Feb 22;8:149. doi: 10.3389/fimmu.2017.00149. PMID: 28275375; PMCID: PMC5319954.

Herath S, Le Heron A, Colloca S, Patterson S, Tatoud R, Weber J, Dickson G. Strain-dependent and distinctive T-cell responses to HIV antigens following immunisation of mice with differing chimpanzee adenovirus vaccine vectors. Vaccine. 2016 Aug 17;34(37):4378-85. doi: 10.1016/j.vaccine.2016.07.028. Epub 2016 Jul 21. PMID: 27452864; PMCID: PMC4978701.

Joachim A, Bauer A, Joseph S, Geldmacher C, Munseri PJ, Aboud S, Missanga M, Mann P, Wahren B, Ferrari G, Polonis VR, Robb ML, Weber J, Tatoud R, Maboko L, Hoelscher M, Lyamuya EF, Biberfeld G, Sandström E, Kroidl A, Bakari M, Nilsson C, McCormack S. Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. PLoS One. 2016 May 18;11(5):e0155702. doi: 10.1371/journal.pone.0155702. PMID: 27192151; PMCID: PMC4871571.

Herath S, Le Heron A, Colloca S, Bergin P, Patterson S, Weber J, Tatoud R, Dickson G. Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen. Vaccine. 2015 Dec 16;33(51):7283-7289. doi: 10.1016/j.vaccine.2015.10.111. Epub 2015 Nov 5. PMID: 26546736; PMCID: PMC4678176.

Knudsen ML, Ljungberg K, Tatoud R, Weber J, Esteban M, Liljeström P. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen. PLoS One. 2015 Feb 2;10(2):e0117042. doi: 10.1371/journal.pone.0117042. PMID: 25643354; PMCID: PMC4314072.

McKay PF, Cope AV, Mann JF, Joseph S, Esteban M, Tatoud R, Carter D, Reed SG, Weber J, Shattock RJ. Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen. PLoS One. 2014 Jan 23;9(1):e84707. doi: 10.1371/journal.pone.0084707. PMID: 24465426; PMCID: PMC3900398.

Weber J, Tatoud R. Testing times for HIV. BMJ. 2013 Sep 18;347:f5556. doi: 10.1136/bmj.f5556. PMID: 24048300.

Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, Simao M, Hankins C, Schwartlander B, Ridzon R, Bazin B, Williams B, Lo YR, McClure C, Montaner J, Hirnschall G; ART in Prevention of HIV and TB Research Writing Group. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res. 2011 Sep;9(6):446-69. doi: 10.2174/157016211798038597. PMID: 21999779; PMCID: PMC3531820.

Weber J, Tatoud R, Fidler S. Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission. AIDS. 2010 Oct;24 Suppl 4:S27-39. doi: 10.1097/01.aids.0000390705.73759.2c. PMID: 21042050.


Fearnside JF, Dumas ME, Rothwell AR, Wilder SP, Cloarec O, Toye A, Blancher C, Holmes E, Tatoud R, Barton RH, Scott J, Nicholson JK, Gauguier D. Phylometabonomic patterns of adaptation to high fat diet feeding in inbred mice. PLoS One. 2008 Feb 27;3(2):e1668. doi: 10.1371/journal.pone.0001668. PMID: 18301746; PMCID: PMC2244706.

Toye AA, Dumas ME, Blancher C, Rothwell AR, Fearnside JF, Wilder SP, Bihoreau MT, Cloarec O, Azzouzi I, Young S, Barton RH, Holmes E, McCarthy MI, Tatoud R, Nicholson JK, Scott J, Gauguier D. Subtle metabolic and liver gene transcriptional changes underlie diet-induced fatty liver susceptibility in insulin-resistant mice. Diabetologia. 2007 Sep;50(9):1867-1879. doi: 10.1007/s00125-007-0738-5. Epub 2007 Jul 6. PMID: 17618414.

Daly-Burns B, Alam TN, Mackay A, Clark J, Shepherd CJ, Rizzo S, Tatoud R, O’Hare MJ, Masters JR, Hudson DL. A conditionally immortalized cell line model for the study of human prostatic epithelial cell differentiation. Differentiation. 2007 Jan;75(1):35-48. doi: 10.1111/j.1432-0436.2006.00113.x. PMID: 17244020.

Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, Fearnside J, Tatoud R, Blanc V, Lindon JC, Mitchell SC, Holmes E, McCarthy MI, Scott J, Gauguier D, Nicholson JK. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12511-6. doi: 10.1073/pnas.0601056103. Epub 2006 Aug 8. PMID: 16895997; PMCID: PMC1567909.

Arya M, Patel HR, McGurk C, Tatoud R, Klocker H, Masters J, Williamson M. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. J Exp Ther Oncol. 2004 Dec;4(4):291-303. PMID: 15844659.

Stephen RL, Gustafsson MC, Jarvis M, Tatoud R, Marshall BR, Knight D, Ehrenborg E, Harris AL, Wolf CR, Palmer CN. Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res. 2004 May 1;64(9):3162-70. doi: 10.1158/0008-5472.can-03-2760. PMID: 15126355.


Tatoud R. Insulin-like Growth Factor (IGF) Network and Prostate Pathologies. Prostate Cancer Prostatic Dis. 1999 Mar;2(2):66-69. doi: 10.1038/sj.pcan.4500295. PMID: 12496840.

Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN. Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol Pharmacol. 2002 Jan;61(1):7-12. doi: 10.1124/mol.61.1.7. PMID: 11752200.

Maillard M, Cadot B, Ball RY, Sethia K, Edwards DR, Perbal B, Tatoud R. Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues. Mol Pathol. 2001 Aug;54(4):275-80. doi: 10.1136/mp.54.4.275. PMID: 11477145; PMCID: PMC1187081.

Sangrajrang S, Denoulet P, Millot G, Tatoud R, Podgorniak MP, Tew KD, Calvo F, Fellous A. Estramustine resistance correlates with tau over-expression in human prostatic carcinoma cells. Int J Cancer. 1998 Aug 12;77(4):626-31. doi: 10.1002/(sici)1097-0215(19980812)77:4<626::aid-ijc24>;2-2. PMID: 9679768.

Sangrajrang S, Denoulet P, Laing NM, Tatoud R, Millot G, Calvo F, Tew KD, Fellous A. Association of estramustine resistance in human prostatic carcinoma cells with modified patterns of tubulin expression. Biochem Pharmacol. 1998 Feb 1;55(3):325-31. doi: 10.1016/s0006-2952(97)00472-3. PMID: 9484799.

Le Moyec L, Millot G, Tatoud R, Calvo F, Eugène M. Lipid signals detected by NMR proton spectroscopy of whole cells are not correlated to lipid droplets evidenced by the Nile red staining. Cell Mol Biol (Noisy-le-grand). 1997 Jul;43(5):703-9. PMID: 9298592.

Lebbé C, Pellet C, Tatoud R, Agbalika F, Dosquet P, Desgrez JP, Morel P, Calvo F. Absence of human herpesvirus 8 sequences in prostate specimens. AIDS. 1997 Feb;11(2):270. PMID: 9030389.

de Cremoux P, Ravery V, Podgorniak MP, Chevillard S, Toublanc M, Thiounn N, Tatoud R, Delmas V, Calvo T, Boccon-Gibod L. Value of the preoperative detection of prostate-specific-antigen-positive circulating cells by nested RT-PCR in patients submitted to radical prostatectomy. Eur Urol. 1997;32(1):69-74. PMID: 9266235.

Prévost G, Benamouzig R, Veber N, Fajac A, Tatoud R, Degeorges A, Eden P. The somatostatin receptor subtype 2 is expressed in normal and tumoral human tissues70. Cancer Detect Prev. 1997;21(1):62-70. PMID: 9043765.

Lebbé C, Tatoud R, Morel P, Calvo F, Euvrard S, Kanitakis J, Faure M, Claudy A. Human herpesvirus 8 sequences are not detected in epithelial tumors from patients receiving transplants. Arch Dermatol. 1997 Jan;133(1):111. PMID: 9006389.

Degeorges A, Tatoud R, Fauvel-Lafeve F, Podgorniak MP, Millot G, de Cremoux P, Calvo F. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer. 1996 Oct 9;68(2):207-14. doi: 10.1002/(SICI)1097-0215(19961009)68:2<207::AID-IJC12>3.0.CO;2-7. PMID: 8900430.

Le Moyec L, Tatoud R, Degeorges A, Calabresse C, Bauza G, Eugène M, Calvo F. Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line. Cancer Res. 1996 Aug 1;56(15):3461-7. PMID: 8758912.

Tatoud R, Degeorges A, Prévost G, Hoepffner JL, Gauvillé C, Millot G, Thomas F, Calvo F. Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro growth inhibitory effect of BIM-23014 analog. Mol Cell Endocrinol. 1995 Sep 22;113(2):195-204. doi: 10.1016/0303-7207(95)03630-p. PMID: 8674827.

Tatoud R, Desgrandchamps F, DeGeorges A, Thomas F. Les facteurs de croissance peptidiques de la prostate [Peptide growth factors in the prostate]. Pathol Biol (Paris). 1993 Oct;41(8):731-40. French. PMID: 7507232.

Desgrandchamps F, Tatoud R, Cussenot O, Teillac P, Le Duc A. Facteurs de croissance prostatiques et hypertrophie bénigne de la prostate. Etat des connaissances actuelles et perspectives [Prostatic growth factors and benign hypertrophy of the prostate. Current knowledge and perspectives]. Prog Urol. 1992 Dec;2(6):1031-44. French. PMID: 1284554.

Le Moyec L, Tatoud R, Eugène M, Gauvillé C, Primot I, Charlemagne D, Calvo F. Cell and membrane lipid analysis by proton magnetic resonance spectroscopy in five breast cancer cell lines. Br J Cancer. 1992 Oct;66(4):623-8. doi: 10.1038/bjc.1992.327. PMID: 1329906; PMCID: PMC1977411.

Le Moyec L, Eugène M, Gauvillé C, Tatoud R, Ouvrard BN, Calvo F. Profils lipidiques de lignées de cancer du sein: spectrométrie par résonance magnétique nucléaire du proton [Lipid profiles of breast cancer cell lines: proton nuclear magnetic resonance spectroscopy]. C R Acad Sci III. 1991;312(1):25-30. French. PMID: 1900730.